RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions
[EN] Lung cancer is the primary cause of cancer-related deaths, with a five-year overall survival rate of 15 %, mainly related to late diagnosis at advanced stages. Despite recent improvements in cancer medicine, metastatic disease still, in fact, represents the main challenge for effective therapies. Targeting disseminated cells requires a better understanding of the underlying biological mechanisms and a paradigm shift to devise innovative treatments. Nanomedicine could open up new perspectives in cancer management, as nanoparticles offer many advantages in drug delivery due to their intrinsic properties, such as better bioavailability and the potential for selective targeting. A strategy to enhance delivery at the site of action is to use nanomedicines targeting specific receptors overexpressed in cancer cells or the tumor microenvironment. We recently identified TAS1R3 as an ideal target, enriched in metastatic lung cancer cells and highly expressed in the CD133+ cancer stem cell (CSC) subset. We developed and evaluated a targeted formulation of sphingomyelin nanoemulsions functionalized with a TAS1R3-specific aptamer (SN-5F). SN-5F exhibited high stability in both aqueous media and biofluids and was efficiently internalized by cell models overexpressing the targeted receptor, including the usually hard-to-target CD133+ CSC population. SN-5F was evaluated in 2D and 3D cell cultures, as well as in vivo using patient-derived xenografts, where it successfully reached disseminated cancer cells and delivered hydrophobic drugs to CSCs, resulting in reduced tumor-forming potential. These results highlight the promise of rationally designed, receptor-targeted nanomedicines as a novel approach for anti-metastatic lung cancer therapy., The authors thank the financial support given by Xunta de Galicia by Grupos de Potencial Crecemento (GPC IN607B2024/14) funded by Axencia Galega de Innovacion (GAIN) , Conselleria de Economia, Emprego e Industria, and RTC2019-07227-1 (Ministry of Economy and Competitiveness, Spain) , co-financed by the European Development Regional Fund "A way to achieve Europe" (ERDF) . This research has been funded by the Instituto de Salud Carlos III (ISCIII) through the grant PI15/00753, CB16/12/00350 Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) , and AC18/00045, co-financed by the European Regional Development Fund (FEDER) by the ERA-NET Euro-NanoMed III, project METASTARG. Funding from Fundacion Cientifica Asociacion Espanola Contra el Cancer (IDEAS18153DELA and LAB-AE211721DELA is also acknowledged. LRC acknowledges Ministerio de Universidades (FPU20/07487) , and SGDA was supported by Xunta de Galicia (ED481A 2022/392) . MM has been funded by the grant PTQ2018-010067 from Ministerio de Ciencia, Innovacion y Universidades by the Spain Government. This work was partly supported by grants from the Italian Ministry of Health (RF-2021-12371959 to LR) , AIRC (IG21431 to LR) and PNRR (PNRR-POC-2022-12376329 to LR) . This work was also supported by the PROMISE project funded through the Caixa Health Research program from La Caixa Foundation (HR20-00637) as well as by the IBEROS+ project (0072_IBEROS_MAIS_1_E) funded through the Interreg POCTEP program. ASM acknowledges the financial support from Fundacao para a Ciencia e Tecnologia (FCT) for the PhD scholarship 2022. 14120.BDANA.
Project:
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) AC18/00045
,
Ministerio de Economía y Competitividad CB16/12/00350
,
Ministerio de Economía y Competitividad PI15/00753
,
Instituto de Salud Carlos III CB16/12/00350
,
Xunta de Galicia ED481A 2022/392
,
Fundação para a Ciência e a Tecnologia 2022.14120.BDANA
,
Portugal PTQ2018-010067
,
Ministerio de Ciencia RTC2019-07227-1
,
Innovación y Universidades PNRR-POC-2022-12376329
,
Ministerio de Economía y Competitividad HR20-00637
,
Ministero dell'Istruzione dell'Università e della Ricerca FPU20/07487
,
Italia RF-2021-12371959